Who
Michael Thomas Heffernan
Director
Company insider
Files Form 4 as: Director, Trevi Therapeutics; Director, enGene Therapeutics; Director, Avalo Therapeutics; Director, Biohaven; Chairman, President and CEO, Collegium Pharmaceutical; Director, Synlogic; Director, Biohaven Pharmaceutical Holding Co; Director, Akebia Therapeutics.
In numbers
- Trades disclosed
- 243
- Buys
- 1
- Sells
- 31
- Bought
- $25K
- Sold
- $26.9M
- Companies
- 11
- Companies where not an officer
- 10
- First trade
- 31 Oct 2008
- Last trade
- 15 Sep 2026
- Last filed
- 17 Sep 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 15 Sep 2026filed 17 Sep 2026 | TRVI Trevi TherapeuticsBiotechnology | SEC FORM 4 Code M | $56K18,421 at $3.04 | filing |
| 15 Sep 2026filed 17 Sep 2026 | TRVI Trevi TherapeuticsBiotechnology | SEC FORM 4 Sold | $276K18,321 at $15.09 | filing |
| 15 Sep 2026filed 17 Sep 2026 | TRVI Trevi TherapeuticsBiotechnology | SEC FORM 4 Sold | $1,588100 at $15.88 | filing |
| 15 Sep 2026filed 17 Sep 2026 | TRVI Trevi Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —18,421 at $0.00 | filing |
| 15 Sep 2026filed 17 Sep 2026 | TRVI Trevi Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —21,052 at $0.00 | filing |
| 15 Sep 2026filed 17 Sep 2026 | TRVI Trevi TherapeuticsBiotechnology | SEC FORM 4 Code M | $70K21,052 at $3.33 | filing |
| 15 Sep 2026filed 17 Sep 2026 | TRVI Trevi TherapeuticsBiotechnology | SEC FORM 4 Sold | $316K20,952 at $15.09 | filing |
| 15 Sep 2026filed 17 Sep 2026 | TRVI Trevi TherapeuticsBiotechnology | SEC FORM 4 Sold | $1,588100 at $15.88 | filing |
| 15 Sep 2026filed 17 Sep 2026 | TRVI Trevi Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —18,421 at $0.00 | filing |
| 15 Sep 2026filed 17 Sep 2026 | TRVI Trevi Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —21,052 at $0.00 | filing |
| 15 Sep 2026filed 17 Sep 2026 | TRVI Trevi TherapeuticsBiotechnology | SEC FORM 4 Code M | $56K18,421 at $3.04 | filing |
| 15 Sep 2026filed 17 Sep 2026 | TRVI Trevi TherapeuticsBiotechnology | SEC FORM 4 Sold | $276K18,321 at $15.09 | filing |
| 15 Sep 2026filed 17 Sep 2026 | TRVI Trevi TherapeuticsBiotechnology | SEC FORM 4 Sold | $1,588100 at $15.88 | filing |
| 15 Sep 2026filed 17 Sep 2026 | TRVI Trevi TherapeuticsBiotechnology | SEC FORM 4 Code M | $70K21,052 at $3.33 | filing |
| 15 Sep 2026filed 17 Sep 2026 | TRVI Trevi TherapeuticsBiotechnology | SEC FORM 4 Sold | $316K20,952 at $15.09 | filing |
| 15 Sep 2026filed 17 Sep 2026 | TRVI Trevi TherapeuticsBiotechnology | SEC FORM 4 Sold | $1,588100 at $15.88 | filing |
| 16 Jun 2026filed 17 Jun 2026 | ENGN enGene Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —31,000 at $0.00 | filing |
| 16 Jun 2026filed 17 Jun 2026 | ENGN enGene Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —31,000 at $0.00 | filing |
| 3 Jun 2026filed 4 Jun 2026 | TRVI Trevi Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —35,000 at $0.00 | filing |
| 3 Jun 2026filed 4 Jun 2026 | TRVI Trevi Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —35,000 at $0.00 | filing |
News
Trevi Therapeutics Announces Oral Presentation Accepted at the CHEST 2026 Annual MeetingTRVI · manilatimes.net · 13 Oct 2026
0 headlines in the last 90 days name Michael Thomas Heffernan; 1 article from the last 14 days about the 1 company they traded most, at most three about any one of them.